Cue biopharma presents positive updated data from its phase 1 trials of cue-101 and cue-102 in head and neck cancer and wt1 positive cancers at the sitc 39th annual meeting

Boston, nov. 08, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of cancer and autoimmune disease, today presented updated data from its phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the immuno-stat™ cue-100 series, cue-101, in patients with recurrent/metastatic head and neck squamous cell carcinoma (r/m hnscc). the data was presented in an oral session at the society for immunotherapy of cancer's 39th annual meeting (sitc 2024) being held in houston, texas and virtually november 6-10.
CUE Ratings Summary
CUE Quant Ranking